Please login to the form below

Not currently logged in

Spectrum appoints chief medical officer

Lee Allen joins from AMAG Pharmaceuticals

Lee Allen, SpectrumDr Lee Allen has joined cancer-focused Spectrum Pharmaceuticals as chief medical officer.

Dr Allen will lead the development of the US-based biotech's pipeline of products, including its investigational cancer drug belinostat, which is due to be filed for approval in mid-2013.

The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at AMAG Pharmaceuticals – the developer of Feraheme (ferumoxytol) for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease.

Prior to this period, he spent four years at Wyeth from 2003 to 2007, serving as VP of clinical R&D for oncology.

Earlier in his career, he also spent time as executive director, site therapeutic area leader for oncology at Pfizer and medical director of oncology and immunology at BASF's Knoll Pharmaceuticals.

"I am very excited to join Spectrum, which I believe has a very promising portfolio of late-stage compounds," said Dr Allen.

"The company has the prospect of being able to introduce two to three new anti-cancer products by 2015 or 2016.”

Dr Allen's predecessor as chief medical officer, Dr Steve Fruchtman, will remain at Spectrum in the newly created role of senior VP, haematology and oncology R&D.

19th March 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...